Proteintech, a global leader in life science solutions, has announced the launch of Able AI, a novel artificial intelligence tool designed to help scientists streamline their research and product development. Now available on the company's website, Able AI is a first-of-its-kind tool that aims to eliminate the guesswork and trial-and-error often associated with selecting suitable antibodies from a vast pool of available products.

The tool provides a user-friendly interface that allows researchers to quickly pinpoint the best antibody for their specific needs. It also offers detailed guidance on experimental procedures and provides relevant scientific knowledge, significantly reducing the time spent on product selection and experimental planning.

This launch is a continuation of Proteintech's commitment to leveraging technology to empower scientists, following its earlier successful introduction of 3D Epitope Mapping, which used AI to help researchers visualize antibody binding sites with greater precision. According to Proteintech CEO Dr. Jason Li, Able AI is a testament to the company's mission to support cutting-edge scientific discoveries by delivering tailored product recommendations and experimental design support. Proteintech, founded in 2001, boasts a portfolio of over 300,000 self-manufactured antibodies and other life science products, and with the introduction of Able AI, it aims to further push the boundaries of the reagent world for the benefit of its customers. The tool is immediately available and free to use.